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Background: E2F1 is the gatekeeper of the cell cycle controlling an analogous balance between proliferation and
cell death. E2F1 expression is elevated in advanced prostate cancer. However, it is still unclear that the roles and
mechanisms of E2F1 on prostate cancers.
Methods: Targeted knockdown by interferon RNA was applied on two prostate cancer and Hela cell lines to examine
the inverse correlation expression of E2F1 and ICAM-1. ICAM-1 promoter reporter and ChIP assays were used for
analysis of the molecular basis of transcriptional regulation of E2F1 on ICAM-1. Co-IP assays were employed for testing
the protein interaction between E2F1 and NF-κB. Tumor xenograft mice model with E2F1 and ICAM-1-knockdown
prostate cancer cells were used to investigate the effects of E2F1 and ICAM-1 on antitumor immunity.
Results: E2F1 knockdown by a specific short hairpin RNA increased gene transcription and protein expression of
ICAM-1. By using wild type and a series of mutant ICAM-1 promoter luciferase constructs, the NF-κB binding sites
were found to be important for E2F1 regulation of ICAM-1 promoter. Targeted knockdown of E2F1 did not affect
expression and phosphorylation of NF-κB and IκBα, but facilitated NF-κB binding to the ICAM-1 promoter, subsequently
induced ICAM-1 transcription and production in prostate carcinoma cells. Furthermore, knockdown of E2F1 inhibited
tumor growth of prostate cancer in vivo through increasing the susceptibility of tumor cells to ICAM-1-mediated
anti-tumor immunity including enhancement of monocyte adhesion, leucocytes infiltration, as well as cytotoxicity
against tumor cells.
Conclusions: E2F1 knockdown inhibited prostate tumor growth in vitro and in vivo through sensitizing tumor cells to
ICAM-1 mediated anti-immunity by NF-κB modulation, highlighting the potential of E2F1 as a therapeutic target.
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Compelling evidences indicate that tumor cells employ
mechanisms that circumvent or thwart the immune re-
sponse to enhance their own growth [1]. Interactions
between the immune system and malignant cells play an
important role in tumorigenesis [2]. Like most types of
cancer, prostate cancer develops in an immune-competent* Correspondence: xyyang@tsmc.edu.cn; xiaow@ustc.edu.cn
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unless otherwise stated.environment. Intercellular adhesion molecule 1 (ICAM-1)
is a cell surface glycoprotein in the immunoglobulin super-
family. ICAM-1 has been implicated in enhancing T-cell
ability to kill targets because of better cell-to-cell adhesion
[3,4]. ICAM-1 can also function to directly costimulate ac-
tivated T cells [5]. ICAM-1 may be involved in tumor sup-
pression through an immuno-surveillance mechanism
[6-9]. It is interesting to explore how transcriptional fac-
tors regulate expression of adhesive molecules required
for immune cytotoxicity against tumor cells.
E2F1 is an intriguing transcription factor that accu-
mulates the integrated signal of the G1/S transition
regulators, required for cell proliferation [10]. Elevated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mRNA and increased expression of E2F1-target genes
DHFR and PCNA, suggesting that E2F1 expression is
elevated in advanced prostate cancer [11]. E2F1 in-
duces tumor cell survival via nuclear factor-kappa B
(NF-κB) dependent induction of EGR1 transcription in
prostate cancer cells [12]. However, it is unknown
whether E2F1 affects ICAM-mediated immunity in
prostate cancer.
In this study, we show that the expression of ICAM-1
is highly inversely regulated by E2F1 in prostate cell
lines. E2F1 knockdown by a specific short hairpin RNA
(shRNA) or small interference RNA (siRNA) increased
gene transcription and protein expression of ICAM-1 in
human prostate cancer cells. Knockdown of E2F1 en-
hances ICAM-1-mediated peripheral blood mononuclear
cells (PBMC) adhesion and cytotoxicity. Furthermore, si-
lencing E2F1 increases ICAM-1 mediated leucocytes in-
filtration and inhibits tumor growth in vivo. By using
wild type and a series of mutant ICAM-1 promoter lu-
ciferase constructs, we found that the NF-κB binding
sites are important for E2F1 regulation of ICAM-1
through disrupting the formation of p65/p50 heterodi-
mer. These results reveal a novel E2F1 mediated signal
circuit for immunoregulation of ICAM-1 beyond its ef-
fect on cell cycle. Furthermore, targeted knockdown of
E2F1 enhances the susceptibility of tumor cells to
ICAM-1-mediated anti-tumor immunity against prostate
cancer.
Results
ICAM-1 expression is inversely correlated with E2F1
expression by prostate cancer cells
To determine whether expression of ICAM-1 was corre-
lated with the amount of E2F1 in DU145 cells, DU145
cells were stably transfected with pU6 + 27 vectors ex-
pressing shRNA of human E2F1. The relative expression
of E2F1 was reconfirmed here by reverse transcriptase
polymerase chain reaction (RT-PCR) and Western blot
(WB) analysis (Figure 1A). The results showed that the
level of transcription and expression of ICAM-1 was in-
duced in the DU145 cells with E2F1-knockdown com-
pared with the control cells, which was also confirmed
by real-time PCR (Figure 1B). Additionally, overexpres-
sion of E2F1 in DU145 cells inhibited the transcription
level of ICAM-1 analyzed by RT-PCR (Figure 1C) and
real-time PCR (Figure 1D). Expression of membrane
ICAM-1 in DU145/sh-E2F1 and control cells was mea-
sured by FACS. As shown in Figure 1E, expression of
membrane ICAM-1 was induced by E2F1 knockdown in
DU145 cells. By interrogating the available microarray
data reported by Singh et al. [13], we also found the ex-
pression levels of E2F1 and ICAM-1 in prostate samples
were inversely correlated, with Spearman’s correlationcoefficient of −0.771 (P < 0.01) (See Statistical analysis in
Methods section).
To further confirm the correlation expression of
ICAM-1 and E2F1, another widely used prostate cancer
cell line PC3 and Hela cells were transiently transfected
with either double strand siRNA-E2F1 or scramble
siRNA (si-Con). Indeed, the expression level of ICAM-1
was increased in both PC3 and Hela cells transfected
with siRNA-E2F1 when compared with the corres-
ponding control cells transfected with scramble siRNA
(Figures 1F and G). These results demonstrated that the
expression of ICAM-1 is highly inversely correlated with
E2F1 expression in both clinical samples and the pros-
tate cancer cell lines, suggesting that E2F1 may be in-
volved in the transcriptional regulation of ICAM-1.
E2F1 affects ICAM-1 transcription through the κB sites on
ICAM-1 promoter
Based on a computational analysis of ICAM-1 promoter,
there is no E2F1 binding motif in the promoter of the
ICAM-1 gene. Previous studies have implicated that
ICAM-1 can be transcriptionally up-regulated by NF-κB
through the proximal NF-κB regulatory region located
between −226 to −217 (5′-GGAAATTCCG-3′) [14,15].
Moreover, it was revealed that there was another poten-
tial NF-κB site at positions −568 to −559 (5′-GG
GGCATCCC-3′) [16]. These two NF-κB sites were then
designated as κB-1 (−568 to −559) and κB-2 (−226
to −217) (Figure 2A).
To explore how E2F1 could transcriptional regulate
expression of ICAM-1, the wild type and a series of mu-
tant ICAM-1 promoter luciferase were constructed and
used to assess whether E2F1 affects activation of ICAM-
1 promoter mediated by the κB sites. A human ICAM-1
promoter (from −891 to −58 upstream of ATG codon)
was cloned from human genomic DNA by PCR and
inserted into the pGL3-basic vector (891-Luc). ICAM-1
promoter mutation constructs designated as κB-1-mut
and κB-2-mut containing point mutations in each corre-
sponding potential NF-κB binding site were created
using site directed mutagenesis. In addition, the ICAM-1
promoter reporter containing both mutation of κB-1
and κB-2 binding site was also constructed and desig-
nated as κB-1/2-mut (Figure 2A). DU145/sh-Con and
DU145/sh-E2F1 cells were transiently transfected with
the ICAM-1 promoter constructs for 48 h and assayed
for luciferase activity. As shown in Figure 2B, the activity
of the wild type 891-Luc promoter in DU145/sh-E2F1
cells was 2.3-fold higher than in DU145/sh-Con cells,
demonstrating that E2F1 knockdown increased ICAM-1
transactivation. Either mutation at κB-1 or κB-2 binding
site equally reduced the regulation from 2.3- to 1.5-fold
in these reporter genes. The double mutated κB-1/2 re-
porter gene had a lower level luciferase activity than that
Figure 1 Expression of ICAM-1 is highly inversely correlated with E2F1 expression. A. ICAM-1 expression in DU145 cells. Whole cell lysates
or total RNA were prepared from DU145 cells stably transfected with either the control vector or shRNA targeting E2F1. The expression of E2F1
and ICAM-1 was monitored by RT-PCR (upper) and Western blot (lower). B. ICAM-1 expression in DU145 cells was analyzed by real-time PCR. The
stars indicate the significant differences (P < 0.05). C. E2F1 overexpression plasmids or control were transient transfected to DU145 cells in a 6-well
plate for 48 h. The expression of E2F1 and ICAM-1 were measured by RT-PCR. D. The expression of E2F1 and ICAM-1 was measured by real time
PCR. The stars indicate the significant differences (P < 0.05). E. Membrane expression of ICAM-1 in DU145/sh-E2F1 and control cells was measured
by FACS. F. siRNA of E2F1 or scramble control was transient transfected to PC3 cells in a 6-well plate for 48 h. The expression of E2F1 and ICAM-1
in these cells were measured by RT-PCR. G. Forty pmol duplex siRNA of E2F1 or scramble control was transient transfected to Hela cells in a
6-well plate for 48 h. The expression of E2F1 and ICAM-1 in these cells were measured by RT-PCR (upper) and Western blotting analysis (lower).
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knockdown of E2F1. These results indicated that E2F1-
regulating suppression of ICAM-1 requires both κB-1
and κB-2 sites.
E2F1 regulates the expression of endogenous ICAM-1
under the conditional loss or inactivation of NF-κB
Having asserted the importance of the NF-κB binding sites
for ICAM-1 gene expression, we next determined whether
loss or inactivation of NF-κB affected the expression of
endogenous ICAM-1. Therefore, we knocked down the
expression of NF-κB p65 subunit using double-strand
siRNA in DU145 cells. Loss of expression of p65 wasconfirmed by Western blot (Figure 2C). Knockdown of
p65 resulted in a dramatically decreased expression of en-
dogenous ICAM-1 and E2F1 knockdown-induced ICAM-
1, indicating a requirement for NF-κB in E2F1 regulating
expression of ICAM-1.
NF-κB inhibitor alpha (IκBα) inhibits NF-κB by masking
the nuclear localization signals of NF-κB proteins and
keeping them sequestered in an inactive state in the
cytoplasm [17]. To functionally inactivate NF-κB, a pCMV-
IκBαM plasmid which contains two mutations that prevent
the phosphorylation step of IκBα was introduced into
DU145/sh-Con and DU145/sh-E2F1 cells. The expression
and activation of IκBα and NF-κB p65 were confirmed by
Figure 2 NF-κB binding sites are required for E2F1 regulation of ICAM-1 promoter. A. The histograph represent the human ICAM-1 promoter
luciferase reporters used in this study. The location of each binding site on the promoter of ICAM-1 is indicated and labeled. The crossed boxes
indicate the mutation sites on each construct. The mutated nucleotides corresponding to κB-1-mut and κB-2-mut are underlined. B and C. DU145/sh-Con
and DU145/sh-E2F1 cells were co-transfected with duplex siRNA targeting p65 and either ICAM-1 wild type or mutant promoter reporters. The
stars indicate the significant differences (P < 0.05) (B). The expression of membrane ICAM-1 was measured by Western blot (C). The data are
shown as the mean ± SD of triplicate measurements. D and E. DU145/sh-Con and DU145/sh-E2F1 cells were transiently transfected with either
the empty vector or the mutant IκBα expressing plasmids. The phosphorylation of p65 and IκBα and the expression of ICAM-1 in these indicated cells
were monitered by Western blot (D). DU145/sh-Con and DU145/sh-E2F1 cells were co-transfected with IκBα expressing plasmids and either the
ICAM-1 wild type or mutant promoter reporters for the luciferase activity assay (E). The results are shown as the mean ± SD of triplicate measurements.
The stars indicate the significant differences (P < 0.05).
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suppressed the level of phosphorylation of p65 and the ex-
pression of ICAM-1. The increase of ICAM-1 expression
induced by E2F1 knockdown was abolished partially by
overexpressing IκBα, though neither the level of expressionnor phosphorylation of NF-κB and IκBα was affected by
knockdown of E2F1.
Next, the effect of E2F1 knockdown on the transacti-
vation of ICAM-1 promoter was examined under the
conditional loss or inactivation of NF-κB (Figures 2B
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were transfected with duplex siRNA of NF-κB/p65
(Figure 2B), the transactivation of the wild type ICAM-1
promoter induced by E2F1 knockdown was significantly
reduced in the case of the decreased p65 level; Similar re-
sults were obtained from the above cells overexpressing
IκBα through transfection of pCMV-IκBαM plasmid
(Figure 2E). The activity of κB-1/2-mut was not induced
in any of these cells. Thus, the NF-κB is required for
E2F1 regulating transcription of ICAM-1.
E2F1 affects NF-κB binding to ICAM-1 promoter
To access whether E2F1 regulates NF-κB binding to the
NF-κB site on ICAM-1 promoter, a chromatin immuno-
precipitation (ChIP) assay was performed (Figures 3A and
B). The cell lysates from DU145/sh-Con and DU145/sh-
E2F1 cells were immunoprecipitated with anti-E2F1 and
anti-p65 antibodies or normal IgG. A pair of primers
flanking the κB binding sites within the ICAM-1 promoter
was used in conventional PCR (Figure 3A) and real-time
PCR (Figure 3B). PCR for the E2F1 binding site within the
CDC2 promoter served as a positive control for detecting
E2F1 binding activity [18]. As expected, E2F1 did not bind
directly to the κB sites within the ICAM-1 promoter.Figure 3 RNA Silencing of E2F1 increases p65/p50 heterdimer bindin
from DU145/sh-Con and DU145/sh-E2F1 cells. The chromatin was immuno
which served as a negative control. A pair of primers flanking the κB-1 bind
E2F1 binding site within the CDC2 promoter served as a positive control fo
the ChIP assay in (A). Relative occupancy values were calculated by determ
amount of immunoprecipitated DNA to that of the input sample) and norm
sh-Con cells, which was defined as 1.0. C. The relationship among E2F1 and
examined by coimmunoprecipitation analysis. Anti-p65 antibody was used
immunoprecipitates were detected by Western blot with the indicated speNevertheless, NF-κB bound to its specific binding sites
and particularly it was significantly increased when E2F1
was depleted in DU145/sh-E2F1. These data strongly sug-
gested that E2F1 may serve as a sequester of NF-κB p65
to prevent it from binding to the ICAM-1 promoter.
Thus, knockdown of E2F1 increases NF-κB binding to
ICAM-1 promoter, resulting in up-regulation of ICAM-1
transcription.
E2F1 interacts with NF-κB p65/p50 heterodimer
To determine how E2F1 prevents NF-κB p65 from binding
to the ICAM-1 promoter, we tested the complex formation
between E2F1 and NF-κB in a co-immunoprecipitation ex-
periment. Cell lysates from DU145/sh-E2F1 and its parent
DU145/sh-Con cells were prepared and immunoprecipated
with an anti-NF-κB p65 monoclonal antibody; immunopre-
cipitates were blotted with anti-NF-κB p65, −NF-κB p50
and anti-E2F1. As shown in Figure 3C, not only did NF-κB
p65 form a complex with NF-κB p50 or NF-κB p65, but
also it associated with E2F1 in DU145/sh-Con cells, dem-
onstrating that a direct physical protein-protein interaction
occurs between E2F-1 and NF-κB. Indeed, the NF-κB p65/
p50 complex was remarkably increased in DU145/sh-E2F1.
These data revealed that E2F1 acts as a suppressor tog to ICAM-1 promoter. A. ChIP assay was performed with cell lysates
precipitated with anti-E2F1 and anti-p65 antibodies or normal IgG
ing site within the ICAM-1 promoter was used in PCR. PCR for the
r detecting E2F1 binding activity. B. Real-time PCR was employed to
ining the apparent immunoprecipitation efficiency (ratios of the
alized to the level of p65 binding with ICAM-1 promoter in DU145/
p65/p50 heterodimer in DU145/sh-Con and DU145/sh-E2F1 cells was
for immunoprecipitation. The amounts of E2F1, p65 and p50 in the
cific antibodies.
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knockdown of E2F1 could enhance formation of NF-κB
p65/p50 heterodimer, resulting in facilitating NF-κB p65
binding to the ICAM-1 promoter and up-regulation of
ICAM-1 transcription.
E2F1 knockdown enhances cell adhesion through ICAM-1
It was reported that interaction between ICAM-1 and its
counter-receptor lymphocyte function-associated antigen
(LFA-1) plays a role in immune cell mediated host defense
mechanisms [19,20]. To study the effect of E2F1 regulating
ICAM-1 on the binding of monocyte to DU145 cells,
cell adhesion assay was performed. The number of the
adhesive peripheral blood mononuclear cells (PBMC)
was increased in DU145/sh-E2F1 cells compared to
control cells (Figures 4A and B). The induction of
adhesion by knockdown of E2F1 was impaired when
the ICAM-1 antibody was pre-incubated with the cells
to block ICAM-1 on cell surface or the expression
of ICAM-1 was knocked down by its specific siRNA
(Figure 4C). These results indicated E2F1 knockdown
could enhance PBMC adhesion to DU145 cells through
up-regulating ICAM-1.Figure 4 E2F1 knockdown enhances cell adhesion through ICAM-1. A
anti-ICAM-1 antibody or transient transfected with duplex siRNA of ICAM-1
After washing three times, attached PBMC were captured using a fluoresce
number of attached PBMC in the (A) was presented by the bar graph (whi
as the mean value ± SD of triplicate measurement. The stars indicate the si
efficiency of the siRNA-ICAM-1 in DU145/sh-Con and DU145/sh-E2F1 cells tE2F1 knockdown increases cytotoxicity of
cytokine-induced killer cells against prostate cancer
cells, correlating with surface expression of ICAM-1
Cytokine-induced killer (CIK) cells are highly efficient
cytotoxic effector cells capable of lysing tumor cell tar-
gets. The cytotoxic effect of CIK cells against tumor tar-
gets is blocked by antibodies directed against LFA-1 and
ICAM-1 [21-23]. The CIK cell subpopulations were
tested for cytotoxicity against the prostate cancer cells as
measured by 51Cr release. The DU145 derived cells were
used as the target cells and the CIK cells as the effector
cells. Both of them at various ratios of effector cells to
target cells were mixed together for evaluating the effect
of E2F1 in regulating ICAM-1 on the CIK cell cytoto-
xicity to DU145 cells. Figure 5A shows the cytotoxicity
of effector cells against DU145 derived prostate cancer
cells. DU145/sh-E2F1 cells showed a higher rate of cell
lysis than DU145/sh-Con cells after co-incubation with
CIK cells for 4 h. DU145/sh-E2F1 cells were found to be
more susceptible to cytolysis by CIK cells than DU145/
sh-Con. As expected, the loss of cell cytolysis was ob-
served in DU145/si-ICAM-1 cells. Furthermore, the in-
duction of cytolysis induced by E2F1 knockdown was. DU145/sh-Con and DU145/sh-E2F1 cells were pre-incubated with
. PBMC labeled with Calcein-AM were added to the indicated cells.
nce microscope at nine randomly selected fields of each well. B. The
te bar, DU145/sh-Con; gray bar, DU145/sh-E2F1). The data are shown
gnificant differences (P < 0.05). C. RT-PCR was employed to validate the
hat were used in (A).
Figure 5 (See legend on next page.)
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Figure 5 RNA Silencing of E2F1 Sensitizes Prostate Cancer Cells to ICAM-1 Mediated Anti-tumor Responses. A. E2F1 knockdown
increases cytotoxicity through ICAM-1. DU145/sh-Con and DU145/sh-E2F1 cells were transiently transfected with duplex siRNA of ICAM-1. The DU145
derived cells were used as the target cells and the CIK cells as the effector cells. Both of them at various ratios of effector cells to target cells were
mixed and cytotoxicity was measured by 51Cr release. The results are shown as the mean ± SD of triplicate measurements. B. The expression of
membrane ICAM-1 in the indicated cells was measured by FACS with ICAM-1 specific antibody. C. The expression of IL-1β, TNF-α, IL-6 and IL-8 in
DU145/sh-Con and DU145/sh-E2F1 cells were measured by real-time PCR. The data presents the fold-induction of the levels of each tested cytokine in
DU145/sh-E2F1 cells over DU145/sh-Con cell, and represent the mean ± SD of triplicate measurements. D. E2F1 knockdown inhibits tumor xenografts
growth in vivo, DU145 cells were stably transfected with the control vectors or shRNA expressing plasmids targeting E2F1 or ICAM-1 respectively and
injected subcutaneously into nude mice. Tumor volumes were measured and estimated by the formula: length (mm) X width (mm) X height (mm)/2.
The results are shown as the mean value ± SD of at least five tumors in each group. E and F. E2F1 knockdown increases ICAM-1-mediated leucocytes
infiltration. The infiltrating leucocytes to DU145-derived tumors in nude mice were stained by H&E and indicated by arrows. The expression of E2F1
and ICAM-1 in these DU145-derived tumors was monitored by immunohistochemistry analysis, H&E staining (D) and Western blot (E).
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shown in DU145/sh-E2F1 + si-ICAM-1 cells. These data
demonstrated that E2F1-mediated increase in ICAM-1
levels plays a role in killing tumor cells, which may repre-
sent another mechanism of the involvement of E2F1 in
tumor growth beyond its effects in cell proliferation.
To get more insight into the potential role of ICAM-
1 in E2F1 controlling target tumor cells susceptibility
to CIK cytolysis, the expression level of ICAM-1 on
the surface of DU145 derived prostate cancer cells was
examined by using flow cytometric analysis (Figure 5B).
As expected, little or no expression of ICAM-1 was
observed on the surface of DU145/si-ICAM-1 cells.
DU145/sh-E2F1 cells showed a higher level of ex-
pression of ICAM-1 compared to DU145/sh-Con cells,
indicating knockdown of E2F1 increased ICAM-1 ex-
pression on the surface of DU145 cells. These data sug-
gested that the lytic capacity of CIK cells correlates
with the expression level of ICAM-1 in DU145-derived
cells modulated by E2F1.
The expression of inflammation cytokines is majorly reg-
ulated by NF-κB and has been indicated in promoting
tumor growth and survival. Since this study revealed that
E2F1 inhibited NF-κB transactivation activity on ICAM-1
expression, it is interesting to examine whether E2F1 affects
the cytokine expressions in the same cell model. As shown
in Figure 5C, the inflammation cytokines including IL-1β,
TNF-α, IL-6 and IL-8 were significantly decreased in
DU145/sh-E2F1 cells compared with DU145/sh-Con cells.
Although the major sources of inflammation cytokines in
tumor microenviroment are coming from the infiltrated
immune cells, the results implicated that the reduction of
these cytokines in DU145/sh-E2F1 may also contribute to
the inhibition of the tumor cell growth. Furthermore, in
contrast with the inhibitory action of E2F1 on NF-κB regu-
lated ICAM-1 transcription (Figures 1, 2 and 3), knock-
down of E2F1 suppressed the expression of the tested
cytokines (Figure 5C), revealing that E2F1 plays different
roles on the transcriptional activities of NF-κB in an regula-
tory sequence specific manner, which is consistent with the
previously reports [24].E2F1 knockdown increases ICAM-1 expression and
suppresses growth of prostate tumor xenografts in a
mouse model
The in vivo effect of E2F1 and ICAM-1 expression on
DU145-derived tumor growth was evaluated in the xeno-
graft mouse model. DU145 cells were stably transfected
with pU6 + 27/shRNA-ICAM-1 plasmids to generate
DU145/sh-ICAM-1 cell lines. Then, DU145/sh-ICAM-1,
DU145/sh-E2F1 and control cells were injected sub-
cutaneously into nude mice respectively. As shown in
Figure 5D, the tumor sizes following inoculation of DU145/
sh-E2F1 cells were smaller than control cells. However, the
size of tumors derived from DU145/sh-ICAM-1 cells was
significantly larger than control. Such difference in xeno-
grafts developed from DU145/sh-E2F1 and DU145/sh-
ICAM-1 cells demonstrated the opposing effects between
E2F1 and ICAM-1 in tumorigenesis of prostate cancer.
More importantly, E2F1 knockdown could inhibit growth
of prostate tumor xenografts in vivo.
Although E2F1 may affect tumor growth through
regulating cell cycle or apoptosis, it is interesting to ex-
plore whether there is another mechanism of the in-
volvement of E2F1 in tumor growth. One critical aspect
of our study was to examine whether knockdown of
E2F1 in DU145 cell-derived tumor tissues is able to in-
crease expression of ICAM-1 and ICAM-1-mediated
leucocytes infiltration in vivo. We performed Western
blot and immunohistochemistry analysis to evaluate the
expression of ICAM-1 and E2F1 in the indicated tumor
tissues. The level of E2F1 in DU145/sh-E2F1 tumors was
reduced compared to DU145/sh-Con. It was observed
that expression of ICAM-1 in DU145/sh-E2F1 tumors
was higher than control and DU145/sh-ICAM-1 tumors
(Figures 5E and F), indicating that the increase in ICAM-1
expression is correlated to suppression of DU145 xeno-
graft tumor growth by E2F1 knockdown.
E2F1 knockdown increases ICAM-1-mediated leucocytes
infiltration in vivo
Tumor infiltration of immune cells mediated by ICAM-
1 was thought to be an attempt by the host organism to
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fect of E2F1 knockdown on ICAM-1-mediated leuco-
cytes infiltration in vivo. The histological observations
by Hematoxylin and eosin (H&E) staining (Figure 5E)
showed that there were no or few leukocytes infiltrated
into the DU145/sh-ICAM-1 tumors. More leukocytes
were infiltrating into the DU145/sh-E2F1 tumors than
into the DU145/sh-Con tumors. Expression of ICAM-1
in tumor tissues was also studied by using immunohis-
tochemistry method. A very weak signal was observed
in DU145/sh-ICAM-1 tumor tissues. ICAM-1 staining
in DU145/sh-E2F1 tumor tissues was remarkably higher
than that in DU145/sh-Con, consistent with the data
obtained from Western blot assay (Figure 5F). These re-
sults suggested that knockdown of E2F1 could increase
on-site leucocytes infiltration to tumors in vivo, which
correlated with expression of ICAM-1.
Discussion
Tumors use multiple mechanisms to escape from immune-
mediated rejection. ICAM-1 has been considered as not
only an adhesion molecule but also a co-stimulatory mol-
ecule that provides signal to cytotoxic T lymphocytes
(CTL) and natural killer (NK) cells. ICAM-1 has been as-
sociated with cellular migration into inflammatory sites
and with facilitating interactions between lymphocytes
and tumor targets in the pathway of cell-mediated cyto-
toxicity [25]. Previous murine studies have shown that the
introduction of the ICAM-1 gene into tumor cells using
retroviral vectors led to enhanced antitumor responses
[5]. Furthermore, numerous studies have documented a
link between the immune infiltrate and response to ther-
apy [26,27]. Vesalainen et al. found that low numbers of
tumor-infiltrating lymphocytes were a sign of high risk of
tumor progression and fatal disease in an analysis with
325 cases with long-term follow-up [28]. In contrast, Kärjä
et al. found that a strong expression of intratumoral T-
cells and B-cells was an independent predictor of short-
ened PSA recurrence-free survival [29]. Our data shows
that E2F1 knockdown increased enhanced leucocytes infil-
tration into tumor tissues and inhibited tumor growth
in vivo. It is interesting to note that the effect of E2F1
knockdown are being evaluated with human cells in vitro
and employing xenograft models, i.e., in a host without an
intact immune system. Most of the mononuclear cells
were murine NK cells due to the lack of T cells in the
nude mouse. Human ICAM-1 has a 53% structural hom-
ology with the murine variant. It has been reported that
murine LFA-1 on NK cells adheres to human ICAM-1 on
tumor cells and provides an anti-tumor effect, and ICAM-
1 plays an important role in cytolysis by NK cells [5,20].
We also observed cytotoxicity of NK cells to cancer cells
was enhanced by increasing ICAM-1 mediated by E2F1
knockdown (Figure 5A). This suggests that the effects ofICAM-1 upregulated by E2F1 knockdown may have im-
portant implications for the systemic treatment of prostate
cancer.
Tanaka et al. found that E2F1 could bind to p65 in
competition with p50, inhibit the formation of functional
p65/p50 heterodimer and suppress the transcription of
MnSOD in murine fibroblasts [30]. It has been reported
that p65/p50 heterodimer binds with the κB site on
ICAM-1 promoter, and actives the expression of ICAM-1
[14]. Our studies showed that the interaction of E2F1 and
p65/p50 also affects the expression of ICAM-1. E2F1 acts
as a suppressor to prevent p65/p50 heterodimer from
binding to ICAM-1 promoter. However, instead of inhibit-
ing gene transcription, Lim et al. reported E2F1 could act
as a transcriptional activator recruited by NF-κB in re-
sponse to LPS [24]. Our previous studies also demon-
strated that E2F1 stimulated the transcriptional activity of
NF-κB on the EGR1 promoter [12]. The significant differ-
ence between the regulation of EGR1 and ICAM-1 by
E2F1 is the binding of E2F1 with the target gene pro-
moter. E2F1 binds to the promoter of EGR1 but not
ICAM-1 (Figure 3). Indeed, a panel of inflammation cyto-
kines including IL-1β, TNF-α, IL-6 and IL-8 are down-
regulated when E2F1 is absented (Figure 5C). These suggest
that E2F1 can positively or negatively regulates NF-κB ac-
tivity, depending on the promoter of the target genes.
Our studies support a model whereby for E2F1 regulation
of tumor immune escape mediated by suppressing ICAM-1
(Figure 6). NF-κB binding sites are important regulatory el-
ements for E2F1 regulation of ICAM-1 (Figure 2). E2F1 in-
teracts with NF-κB forming an E2F1/NF-κB complex. Such
molecular interplay between E2F1 and NF-κB in the
regulation of ICAM-1 is dependent on p65. E2F1 acts as
a suppressor to prevent the NF-κB p65/p50 complex
from binding to ICAM-1 promoter. When E2F1 is tar-
geted knockdown by shRNA-E2F1, which does not affect
expression and phosphorylation of NF-κB/p65 and IκBα,
but facilitates NF-κB binding to the ICAM-1 promoter
(Figure 3), ICAM-1 transcription and production are
subsequently induced, resulting in antitumor immunity
against prostate carcinoma cells.
Conclusions
Taken together, our data provided the evidence that E2F1
influences the ICAM-1 mediated anti-tumor microenvir-
onment immune circuit through NF-κB modulation,
which regulates prostate cancer cells escape from immune
responses. A functional interaction between E2F1 and NF-
κB regulates ICAM-1 transcription and production. Tar-
geting knockdown of E2F1 resulted in the induction of
ICAM-1 production and ICAM-mediated anti-tumor
immunity to prostate cancer cells, highlighting a new
functional signal circuit of E2F1 on immunoregulation
of ICAM-1 beyond cell cycle and the potential of E2F1
Figure 6 A schematic model whereby E2F1 regulates the ICAM-1 mediated anti-tumor immune circuit through NF-κB modulation.
NF-κB binding site is required for E2F1 regulation of ICAM-1. E2F1 interacts with NF-κB forming an NF-κB/E2F1 complex. E2F1 acts as a suppressor
to prevent the NF-κB p65/p50 complex from binding to ICAM-1 promoter. As a consequence, E2F1 interferes with the adhesion of monocytes
onto prostate cancer cells, the sensitivity of tumor cells to the cytotoxic effect of cytokine-induced killer cells and the growth of prostate cancer
cells. Targeted knockdown of E2F1 does not affect the expression of phosphorylation of NF-κB p65 and IκBα, but releases NF-κB p65 to facilitate
p65/p50 heterodimerization and binding to the ICAM-1 promoter. Subsequently, ICAM-1 transcription and production are induced, resulting in
the enhanced immune cells mediated cytotoxicity against prostate carcinoma cells.
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Cell culture components were purchased from Gibco. The
following specific antibodies were used in this study: anti-
p65, anti-p50, and anti-E2F1 polyclonal antibodies (Santa
Cruz Biotech); anti-ICAM-1, anti-IκBα, anti-GAPDH, anti-
phosphorylated p65 (p-Ser276), and anti-phosphorylated
IkBα (p-Ser32/36) monoclonal antibodies (Cell Signaling);
and PE mouse anti-human ICAM-1 antibody (BD Biosci-
ences). pCMV-IκBαM plasmid was purchased from Clon-
tech. pcDNA-E2F1 plasmid was a gift from Dr. Mian Wu.
All other reagents and chemicals used for this study were
purchased from Sigma-Aldrich, Inc.
Short hairpin RNA (shRNA) expression and small
interfering RNA (siRNA) duplex
Two types of RNA interference were used to knockdown
the expression of E2F1 and ICAM-1, which were shRNA
expression plasmids and duplex siRNA. The pU6 + 27/
shRNA expression vectors of human E2F1 were con-
structed as described in previous study, which targeting
amino acids 125 to 131 of human E2F1 [12].
Cell culture and transfection
DU145, PC3 and Hela cells were purchased from Ameri-
can Type Culture Collection (ATCC) and cultured at 37°C
with 5% CO2 in complete DMEM (Gibco) supplementedwith 10% fetal bovine serum (FBS) and 2 mmol/L of L-
glutamine. Lipofectamine 2000 (Invitrogen Corporation)
was used for transfection. Stably transfected cell lines with
pU6 + 27/shRNA expression vectors were obtained after
being selectively screened by G418 (800 μg/ml).
Construction of luciferase reporter plasmids
The ICAM-1 promoter region (bp −897 to −58 upstream
of the translation initiation site) was amplified by polymer-
ase chain reaction using human genomic DNA (Clontech)
as a template with the primers ICAM-1(−897): 5′-AGG
GAG CTC TCG TCA AGA TCC AAG CTA GCT G-3′
and ICAM-1(−58): 5′-GGA AGA TCT GTG ATC CTT
TAT AGC GCT AGC C-3′. A series of luciferase reporters
were then constructed by site-directed PCR mutagenesis
using the 897-luc plasmid as the template and a set of
primers containing the corresponding point mutations on
the NF-κB binding sites. The primers for generating
the point mutation on the NF-κB binding sites are: 5′-
GAG GGA TGC GAT TCC CCC TAG GTC ACG TCC
AC -3′ and 5′ – TAG GGG GAA TCG CAT CCC TCA
GTG GAG GGA G -3′ for NF-κB binding site-1; 5′-
TGG CCG CTT CAG CTC CGG AAT TTG GAA GC -3′
and 5′- GCC GCC CGA TTG CTT TAG CTT CCA AAT
TCC -3′ for NF-κB binding site-2. The point mutations are
indicated as Italics.
Flow cytometry analysis
The cells were washed with PBS and incubated with PE
conjugated anti-ICAM-1 antibody for 30 min. An aliquot
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Reverse transcription-PCR and Real-time PCR
Isolated total RNA was subjected to cDNA synthesis by
Superscript III reverse transcriptase (Invitrogen). PCR
products were quantitated by agarose gel electrophoresis
or real-time PCR using an ABI7500 instrument (Applied
Biosystems) and FastStart Sybr Green Master kit
(Roche). The following primer sets were used for PCR:
humanE2F1-RT-sense: 5′-GTC ACG CTA TGA GAC
CTC AC-3′, humanE2F1-RT-antisense: 5′-TCA AGG
ACG TTG GTG ATG TC-3′; beta-actin-sense: 5′-GAC
CTG ACT GAC TAC CTC ATG AAG AT-3′, beta-actin-
antisense: 5′-GTC ACA CTT CAT GAT GGA GTT GAA
GG-3′; humanICAM-1-sense: 5′-TTC TCG TGC CGC
ACT GAA CTG-3′, humanICAM-1-antisense: 5′-GAG
TCG TTG CCA TAG GTG ACT G-3′; humanIL-1β-
sense: 5′-AGC TAC GAA TCT CCG ACC AC-3′,
humanIL-1β-antisense: 5′-CGT TAT CCC ATG TGT
CGA AGA A-3′; humanTNF-α-sense: 5′-CCT CTC TCT
AAT CAG CCC TCT G-3′, humanTNF-α-antisense: 5′-
GAG GAC CTG GGA GTA GAT GAG-3′; humanIL-6-
sense: 5′-CCA GGA GCC CAG CTA TGA AC-3′,
humanIL-6-antisense: 5′-GAT GCC GTC GAG GAT
GTA CC-3′; humanIL-8-sense: 5′-AAG CTG GCC GTG
GCT CTC TT-3′, humanIL-8-antisense: 5′-TGT TGG
CGC AGT GTG GTC CA-3′.
Luciferase reporter assay
Cellular lysates were subjected to a dual-luciferase re-
porter assay (Promega) according to the instructions of
the manufacturer. Briefly, an appropriate amount of the
ICAM-1 promoter luciferase reporters, together with
Renilla luciferase plasmids, which served as the internal
control, were cotransfected into cells. 36 h later, cellular
lysates were subjected to a dual-luciferase reporter assay.
The luciferase activities for the promoter reporters were
detected by GloMax® 96 Microplate Luminometer (Pro-
mega) and normalized to Renilla luciferase activities.
The data represented at least three independent expe-
riments. Significant differences were analyzed using the
Student’s t test. A value P < 0.05 was considered statisti-
cally significant.
Chromatin immunoprecipitation assay
Cells were cross-linked with 1% formaldehyde at room
temperature for 10 mins and then quenched using
125 mmol/L glycine. The lysate was sonicated to shear
the chromatin DNA to about 500 bp.The pre-cleared
chromatin solutions were incubated with specific anti-
bodies or normal IgG for control. The immunocomplexes
were captured with ssDNA/Protein A agarose beads. After
extensive washing, the bound DNA fragments were elutedby heat treatment (65°C overnight) and proteinase K di-
gestion. The eluted genomic DNA fragments were ana-
lyzed by both conventional PCR and real-time PCR. The
following primer sets were used for PCR: ICAM1pro-κB-
Fw: 5′- CAC TCC CAC GGT TAG CGG -3′ and
ICAM1pro-κB-Rv: 5′- CCA TTT CAC AAA GCG GTA
AAC -3′; CDC2pro-E2F-Fw: 5′– TGG AGG AGA GCG
CTT GCG CTC GCA -3′ and CDC2pro-E2F-Rv: 5′-
TTT CAA ACT CAC CGC GCT AAA GG -3′. The PCR
products were separated using 2% agarose gel and visual-
ized by ethidium bromide. The CDC2 promoter fragment
acted as the positive control of bound of E2F1 [18]. For
real-time PCR, relative occupancy values were calculated
by determining the apparent immunoprecipitation effi-
ciency (ratios of the amount of immunoprecipitated DNA
to that of the input sample) and normalized to the level of
a control sample, which was defined as 1.0. The data rep-
resented at least three independent experiments. Signifi-
cant differences were analyzed using the Student’s t test. A
value P < 0.05 was considered statistically significant.
Cytokine-induced killer cells
Human peripheral blood mononuclear cells (PBMC) were
separated by Ficoll density gradient centrifugation. Adher-
ent cells were removed by adherence to plastic surfaces,
Nonadherent cells were resuspended were re-suspended
at 1X106 cells/ml in GT-T551 medium (TAKARA, Japan)
containing 10% fetal bovine serum (GIBCO, CA, USA)
and cultured in the presence of immobilized anti-CD3
antibody (10 μg/108 cells, BD Pharmingen, NJ, USA), re-
combinant human IFN-γ (1000 U/ml, R&D systems, MN,
USA) and recombinant human IL-2 (1000 U/ml, R&D
systems, MN, USA) for 21 days. Fresh IL-2, IFN-γ and
medium were replenished every two or three days.
Cell adhesion assay
DU145 cells were grown in 6-well tissue culture plates.
2X105 Calcein-AM (Molecular Probe) labeled PBMC per
well were added to the DU145 and incubated for 60 mi-
nutes in a 37°C, 5% CO2 incubator. After washes, cultures
were fixed with 4% paraformaldehyde, and the pictures of
attached monocytes were captured and counted using a
fluorescence microscope at nine fields of each well.
51Cr release assay
Cytotoxicity was examined by standard chromium 51
(51Cr) release assays. Briefly, one million target cells
(DU145 cells) were labeled with 50 μCi sodium chro-
mate for 4 hour at 37°C and washed three times. Effector
cells (CIK cells) and target cells (DU145 cells) were incu-
bated for 4 hours at the indicated E:T ratios. The radio-
activity was measured in a gamma counter. The percentage
of specific lysis was calculated according to the following
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Nude mouse xenograft assay
BALB/c nude mice (6–8 weeks old) were housed under
specific pathogen-free condition. On day 0, 5 million
DU145 cells in 200 μL of PBS were injected subcutane-
ously into nude mice. Tumor volumes were measured and
estimated by the formula: length (mm) X width (mm) X
height (mm)/2. On day 42, the mice were sacrificed and
the tumor weights were measured. The animal experi-
ments have been approved by the appropriate review
board (School of Life Science, University of Science and
Technology) and conform to local laws and regulations.
Immunohistochemistry
Paraffin-embedded sections were deparaffinized, rehy-
drated, and subjected to antigen retrieval in 10 mmol/L
citrate buffers, pH 6.0. The following primary antibodies
were used: rabbit anti-E2F1 antibody (1:500) and rabbit
anti-human ICAM-1 antibody (1:500). Immunoreactivity
was detected using 3, 3’-diaminobenzidine substrate.
Statistical analysis
Data are expressed as the mean value ± standard deviation
(SD) of at least triplicate independent determinations for
the quantitative assays in this study. Significant differences
were analyzed using the Student’s t test. A value P < 0.05
was considered statistically significant. Spearman’s rank
correlation coefficient was calculated by SPSS (Statistical
package for the social sciences) software and used to in-
vestigate the relationship between the expression level of
E2F1 and ICAM-1 using the microarray data from clinical
prostate samples reported by Singh et al. [13].
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